Myasthenia gravis is an autoimmune disease of acquired neuromuscular junction transmission disorder mediated by autoantibodies, of which acetylcholine receptor antibodies are its most common pathogenic antibodies, and cholinesterase inhibitors are the drugs of choice for initial treatment. Here, BCHE is linked to autoimmune disease.